Skip to main content

1 Result(s)

within Ann Kelley Remove this filter

and

  1. No Access

    Article

    Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer

    We undertook a preliminary study to examine the response rate of recombinant interleukin-2 (rIL-2) in patients with advanced measurable breast cancer, in a phase II clinical trial. The regimen we utilized was ...

    Darcy V. Spicer, Ann Kelley, Robin Herman, Grace Dean… in Cancer Immunology, Immunotherapy (1992)